Corsight’s Upcoming DNA to FACE: 'Terrifying' Warns Privacy Expert
Corsight plans to release a new product that combines DNA and face recognition technology and could have significant law enforcement and privacy implications.
In this report, we examine Corsight’s product roadmap for "DNA to FACE," presented at the 2021 Imperial Capital Investors Conference, possible use cases for the technology, and warnings from a privacy expert.
IPVM collaborated with MIT Technology Review on this report, see the MIT Technology Review article: This company says it’s developing a system that can recognize your face from just your DNA
Corsight’s ******* - *** ** **** *********
** ******** ****, **** ******** * presentation ** ********'* ***,****** *****, *** *** ** ******** ***********,**** *****, ** *** ******** ******* ********* Conference ** *** ****.
********'* *** ******* *******, ***** *****, included ***** ********: "***** ** ****," "DNA ** ****," *** "********".
** *** *****, ******** ********* "*** to ****" **:
********** * ******** ******* ** ********* genetic ******** ********* ** * *** sample
***** ** **** ************, **** *** unaware ** * ******* ********** ** commercialize * **** *********** ******* ********** with * *** ******.
******** *** *** ******* ******* ** how "***** ** ****" ***** ****. The *******'* *********** ** "********" ** more ******** ***** ** **** ***********. IPVM********** ************ ******** *** *** ***********.
"Company ************" - ******** ****** ** ******
**** ***** ******** ***** "*** ** FACE" *** *** ******** ***. ***** replied ** **** ***, ****** *************** concerns, ******** ** ******* "*** ** FACE" *******. *******, *** *** ********* that ******** ******* ** ****** *** product.
** *** *** ******** **** *** press ** *** ****** ** *** details ** **** ** *** ***** arecompany ************. We will release information once *** ****** ** *********.
Privacy ******: ********** "**********"
**** *** *** ********** ****** ***** with ******* ************ *** ****,******* ** *************** ********** ********* *******. **** ****** ******** ** ********* bias *** ******** *** ***** ********** with ********* *** **** **** *********** technology, ******* *** *********** '**********':
*** **** **** ***'** *** ***** try ** ******* *** *** ************ isreally ********** because not just because of the obvious potential drive of bias ********, *** **** *** ******** *** ***** ****.
**** **** ********** *** *********** ** such **********:
*** **** ***'** ***** ** **** to *** * ****** *********** ****** against * ********* ***** *** **** anything *********** ******** ******* ** ** is **** *staggering *****, ** **** ***** *************.
*** ** *** **** **** ***'** gonna ** **** ** ****** ********* with *** ***** ** *********** *** fidelity, ****'* ********* ** *** * face ***** ****** ** **,that's ************, **** ** *************.
Possible *** ***** *** *** ** ****
***** ******** ******** ** ********* ** specific *** *****, *** **** ***** stated ****** ********’* ************ **** *** progression ** ** *** ******* ******** have **** **** ********** **********.
*** ** *** ********* *** **** for ********* *** *** ************ ** law *********** *** ******** ******** ** crime ******. *** *******, ******** * composite ***** ** * ******* **** DNA ***** ** * ***** ***** would ****** ************* ** ***** *** image ** ******** ***** ********* ** show ** *********. ************, **** ********** could **** ** **** ** ******* cold ***** ********* *** ********.
*******
******** ***** *********** ********** ** *** commercialization ** "*** ** ****." ******* the ******** *** ***** *** *** clear *** *** ******** ** ********'* technology ** *******. ** *** ******* is ********** ********, ** ******** *******, "DNA ** ****" **** **** **** scrutiny **** *** ***********/***** *** *******-****** perspectives.
* ********** **** **** ********* **** this, **** *** ******* ****** ****** about *** ******** **** **, **** start ** ****** *** ****. **** is *** * **** **** ********* should ****** * ******* **** ** rights **** ******** * ***** ** privacy *** ** ** ********* **** the ********.
**** ** *** ******* ** **** tech ** *********** ***** ********** ******'* *****:
********’* **** ** *** ******** ***. Human *********, * “********-*****, ****** ************” company ******* ** ******* ****** *********** Craig ****** ******** *********, ******* ** ******** *** ** ******* ******* ****. *** ********** ****** ******** then ***********, *******, **** ********. * ****** ******** ** ***** Longevity **** *** ******* ***’* **** a ****** *** ** * ***** using * ******, *** ***** ******, chief ******* ******* ** *** ********* platform **********,********* * ******** ****** *** ***** flaws** *** ********.
**** ******** ********* ** ****** **************:****** *********** **** *** ***** ****-**-*** classifiers********* **** * ***********:
**** ******** ********* ** ****:************** ** *********** ** ***** ********** using *****-****** ********** ********* **** ****** **** ** ******, skin ***** *** *** ***** **** predicted **** **** ********. *******, **** complex ****** **** **** ********.
** ********* *********** ****** ****** **** as *** *****, **** *****, *** sex ** **** ********. *******, *** complex ******, *** ****** ********* **** small ********* ** *** ******** ********** variation.
******** ********* "*** ** ****" **: "Constructs * ********profile by analyzing genetic material collected in a DNA sample" [empasis added]
**** ******* ** ** * **** bad **** ** ********* ******* *** much *********** ******** ** ** **********'* face *** **** ***** ** *** from ***? **** *** ***** ********, it ******* **** ******.
** ********* *********** ****** ****** **** as *** *****, **** *****, *** sex ** **** ********. *******, *** complex ******, *** ****** ********* **** small ********* ** *** ******** ********** variation.
****'* *** ******** ***** ** ****** facial *********** ** ** ** ******** used, *.*., *********** * ******** ****, not ******** ** **** ***** *** sex.
* **** *********** ******* *****.
***** * ***** **** ** ********* to ** **** ** ******** *******, specific, ******* *** ******** ************** **** DNA, ***, **** *** **** ****** for ******* ****** ** **** ***, to * ******, ************ ************. *** the **** **** *** ***** *** DNA ** *********** **** * **** would **** ****? **** ** **** aspects ** *** *** ******** ****** in * ***** *** *****? **** sounds **** *** ***** **** ** pseudo-science *******.
**** **** **** ****** ********* ** this. ** ********* ******* ** ** implausible ******** ******** (**** **** ** 23andme *********** *** ** *** - they ****** ******* ********* ****** ** percent ********** ** **** * ***** most ****** ******* ********, **** ****** they **** **** ** ******* *** the ** *******). *** *** ***** thing ** **** **** ***** *** get ******** *** * ********* ******** interest, ** *** **** *** **** with ******* ***** ******* *********, **** as *** *** ********** ******** ****** and ********* ****** **** * *****!
****** * ***** ** *** **** could ** ****, * ***** ****** you ***** ******* *** **** ** process. ***** *** ** **** **** undeniable ******** *** ******** *** ********* confirmation. ** ************* ** ******* *** from * ***** ***** *** ***** perhaps ** * ******* **** ** in * *** ******** *** ********* of *** ******* (******** *** **** access ** **** *********) *** ******* a ****** **** ***** ** **** they ***** **** **** ***** ** nearest ** ********* *********, ********** ** several *** ******* (****/*** ******, ***,***) are ******* ******** ******* *** ******* DNA *******. ** *****'* *********** ********* accuracy *** *** ****, *** ** is * ***** ** ********* ** the *************. *** *********** ** **** capabilities ***** ****** ** ******** *** one ** *** **** ***** ** the ******* ******...
******* ******* ** ** *** *** to ******* * *** ****** 😂
***** * ** *** **** **** Corsight's ********** *** **** *** ******, this **** ******* *******'* ***** ****** ** ****** aggressive ******. *** *******, *** *** *** circle ***** ****** * ******* ****** recognition ***** ** *** *******'* ********* below:
**** ***** ******** ** **, **** genuinely ******* **** *** ******** *** accurately ** ***** ******, **** ***** where **** ********* * **** ("*** Williams") ** * "*** ********** ******", with * **+ ***** ***** ** View, ** * ****** ******* * mask ** * *** ***** ** the ******.
* ***** ********* **** **** *** claim ***********, ** ***** ** ***** to ***** **** ** ** ******** conference *** *'* ** ********* ***** this ******** * ********** ********** ******** for ****.